Analysts Set Carisma Therapeutics, Inc. (NASDAQ:CARM) Price Target at $4.94

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) have received an average rating of “Hold” from the seven research firms that are presently covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $4.94.

Several research firms have recently weighed in on CARM. Baird R W downgraded shares of Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 12th. BTIG Research lowered shares of Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 10th. Robert W. Baird downgraded Carisma Therapeutics from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $10.00 to $1.00 in a research report on Thursday, December 12th. Evercore ISI reiterated an “in-line” rating and issued a $0.70 price target (down from $4.00) on shares of Carisma Therapeutics in a research report on Wednesday, December 11th. Finally, D. Boral Capital reissued a “buy” rating and set a $12.00 price objective on shares of Carisma Therapeutics in a report on Monday, January 13th.

Carisma Therapeutics Trading Down 4.8 %

Shares of CARM opened at $0.39 on Friday. Carisma Therapeutics has a fifty-two week low of $0.38 and a fifty-two week high of $2.60. The business has a 50-day moving average of $0.45 and a 200 day moving average of $0.69. The firm has a market cap of $16.44 million, a P/E ratio of -0.25 and a beta of 1.55. The company has a debt-to-equity ratio of 1.39, a quick ratio of 3.23 and a current ratio of 3.23.

Institutional Investors Weigh In On Carisma Therapeutics

Large investors have recently added to or reduced their stakes in the business. Wexford Capital LP increased its stake in Carisma Therapeutics by 75.5% in the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after acquiring an additional 15,000 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Carisma Therapeutics by 11.9% during the fourth quarter. Renaissance Technologies LLC now owns 231,357 shares of the company’s stock worth $97,000 after purchasing an additional 24,600 shares in the last quarter. Finally, Barclays PLC increased its position in shares of Carisma Therapeutics by 3,661,933.3% in the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after purchasing an additional 549,290 shares during the last quarter. Institutional investors own 44.27% of the company’s stock.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.